Spruce Biosciences (SPRB) Non-Current Deferred Tax Liability (2022 - 2023)
Spruce Biosciences (SPRB) posted quarterly Non-Current Deferred Tax Liability of $1000.0 for Q4 2023, down 99.75% year-over-year from $394000.0 in Q4 2022, and down 99.75% quarter-over-quarter from $394000.0 in Q4 2022.
Spruce Biosciences (SPRB) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Spruce Biosciences (SPRB) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $1000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Non-Current Deferred Tax Liability fell 99.75% year-over-year to $1000.0; the TTM figure through Dec 2023 stood at $1000.0 (down 99.75% YoY), while the FY2023 annual figure was $1000.0, down 99.75% from the prior year.
- Non-Current Deferred Tax Liability slipped to $1000.0 in Q4 2023 per SPRB's latest filing, from $394000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $394000.0 in Q4 2022 and bottomed at $1000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 394,000.00 |
| Dec 31, 2022 | 394,000.00 |